Cancer cell-derived exosomal circUSP7 induces CD8+ T cell dysfunction and anti-PD1 resistance by regulating the miR-934/SHP2 axis in NSCLC

[1] Sung H(2021)Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 71 209-249

[2] Ferlay J(2017)Nivolumab versus Docetaxel in previously treated patients with advanced non-small-cell lung Cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057) J Clin Oncol 35 3924-3933

[3] Siegel RL(2019)Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung Cancer Cancer Res 79 1214-1225

[4] Laversanne M(2018)SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo Nat Med 24 961-967

[5] Soerjomataram I(2004)SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation J Immunol 173 945-954

[6] Jemal A(2001)PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine Proc Natl Acad Sci U S A 98 13866-13871

[7] Bray F(2005)CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms Mol Cell Biol 25 9543-9553

[8] Horn L(2012)Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2 J Exp Med 209 1201-1217

[9] Spigel DR(2004)PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta FEBS Lett 574 37-41

[10] Vokes EE(2016)Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases Nature 535 148-152

[1] Sung H(2021)Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 71 209-249

[2] Ferlay J(2017)Nivolumab versus Docetaxel in previously treated patients with advanced non-small-cell lung Cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057) J Clin Oncol 35 3924-3933

[3] Siegel RL(2019)Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung Cancer Cancer Res 79 1214-1225

[4] Laversanne M(2018)SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo Nat Med 24 961-967

[5] Soerjomataram I(2004)SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation J Immunol 173 945-954

[6] Jemal A(2001)PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine Proc Natl Acad Sci U S A 98 13866-13871

[7] Bray F(2005)CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms Mol Cell Biol 25 9543-9553

[8] Horn L(2012)Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2 J Exp Med 209 1201-1217

[9] Spigel DR(2004)PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta FEBS Lett 574 37-41

[10] Vokes EE(2016)Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases Nature 535 148-152